Moshe Weinstein

Company: Everads Therapy

Job title: Chief Executive Officer

Seminars:

Rapid Delivery of Therapy to the Macula using Novel Suprachoroidal Delivery Technology 9:00 am

Achieving rapid and extensive coverage of the posterior coverage in non-human primates and pigs leveraging a novel delivery technology Compatibility and experience with gene therapy, demonstrating AAV-GFP expression at the macula in various non-human primate studies up to 85 days post injection Update on first-in-human clinical trial using Everads’ suprachoroidal delivery technologyRead more

day: Conference Day Two